Description
Alluvi™ Retatrutide is an advanced investigational injectable therapy targeting GLP-1, GIP, and glucagon receptors for a triple-action approach to weight loss, glucose control, and metabolic health. Developed as part of next-generation incretin-based therapeutics, Retatrutide has shown superior efficacy in early clinical trials compared to semaglutide and tirzepatide.
Key Benefits:
- Triple receptor agonist for enhanced appetite suppression and calorie control.
- Significant weight loss potential (up to 24% average body weight reduction in studies).
- Improves glycemic control and insulin sensitivity.
- Potential cardiovascular and liver health benefits.
- Once-weekly subcutaneous injection.
Clinical Indications:
- Obesity management (BMI ≥30)
- Overweight patients with comorbidities (BMI ≥27)
- Adjunct to diet and exercise for type 2 diabetes (pending approval)
Dosage & Administration:
- Standard dosing: Once weekly subcutaneous injection.
- Starting dose and titration schedule determined by healthcare provider.
- Supplied in prefilled pen format (varied mg strengths available).
marc –
It’s a pleasure to order from you, Mr Rahman
They are great products
softy –
love it, thanks Dr. Rahman
Ali –
Great product you have got, thanks for the delivery. At first, I doubted you, haha, but I got